Stanford University
Showing 34,031-34,040 of 37,041 Results
-
Sophia Y. Wang, MD, MS
Assistant Professor of Ophthalmology
Current Research and Scholarly InterestsI use and integrate a wide variety of data sources in my research, spanning both structured and unstructured forms, including national survey datasets, health insurance claims data, patient generated online text, surgical video, and electronic health records. I investigate outcomes of treatments for glaucoma and cataract, as well as other areas of ophthalmology. My focus is on developing artificial intelligence methods to predict ophthalmology outcomes, while ensuring fairness.
-
Sui Wang, PhD
Associate Professor of Ophthalmology
Current Research and Scholarly InterestsOur research focuses on unraveling the molecular mechanisms underlying retinal development and diseases. We employ genetic and genomic tools to explore how various retinal cell types, including neurons, glia, and the vasculature, respond to developmental cues and disease insults at the epigenomic and transcriptional levels. In addition, we investigate their interactions and collective contributions to maintain retinal integrity.
1. Investigating retinal development:
We utilize genetic tools and methods such as in vivo plasmid electroporation and CRISPR to dissect the roles of cis-regulatory elements and transcription factors in controlling retinal development.
2. Understanding diabetes-induced cell-type-specific responses in the retina:
Diabetes triggers a range of multicellular responses in the retina, such as vascular lesions, glial dysfunction, and neurodegeneration, all of which contribute to retinopathy. We delve into the detailed molecular mechanisms underlying these diabetes-induced cell-type-specific responses and the pathogenesis of diabetic retinopathy.
3. Developing molecular tools for labeling and manipulation of specific cell types in vivo:
Cis-regulatory elements, particularly enhancers, play pivotal roles in directing tissue- and cell-type-specific expression. Our interest lies in identifying enhancers that can drive cell type-specific expression in the retina and brain. We incorporate these enhancers into plasmid or AAV-based delivery systems, enabling precise labeling and manipulation of specific cell types in vivo.
